2014-004560-38
The purpose of this study is to demonstrate the efficacy and safety of adalimumab for the induction of clinical remission in Japanese subjects with Crohn's disease.
Abbott Deutschland GmbH & Co. KG·EU Clinical Trials Register
Study focus
- Disease/Condition
- Crohn's Disease
Sponsor & location
- Primary sponsor
- Abbott Deutschland GmbH & Co. KG
- Funder
- Abbott Japan
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
•Ulcerative colitis or indeterminate colitis
ICD-10 classifications
Crohn disease, unspecifiedOther Crohn diseaseCrohn disease of large intestineCrohn disease [regional enteritis]Crohn disease of small intestine
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2014-004560-38
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2014-004560-38 through Pure Global AI's free database. This phase not specified trial is sponsored by Abbott Deutschland GmbH & Co. KG and is currently status unknown. The study focuses on Crohn's Disease.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.